Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KCNB1 | Q14721 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10262220 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRMMP2KMT2ACA1 | |
| SCHEMBL12515508 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRMMP2KMT2ACA1 | |
| SCHEMBL15277753 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRMMP2KMT2ACA1 | |
| SCHEMBL21371949 | 0.96 | CA1 (0.40) | ALDH1A1TSHRMMP2KMT2ACA1 | |
| SCHEMBL19486135 | 0.96 | CA1 (0.40) | ALDH1A1TSHRMMP2KMT2ACA1 | |
| SCHEMBL13973798 | 0.93 | ALDH1A1 (0.37) | ALDH1A1TSHRMMP2KMT2ACA1 | |
| SCHEMBL13973875 | 0.92 | NPY4R (0.41) | TSHRMMP2KMT2ALMNAKCNB1 | |
| SCHEMBL10199252 | 0.92 | NPY4R (0.41) | TSHRMMP2KMT2ALMNAKCNB1 | |
| SCHEMBL12514984 | 0.92 | NPY4R (0.41) | TSHRMMP2KMT2ALMNAKCNB1 | |
| SCHEMBL10262865 | 0.92 | NPY4R (0.41) | TSHRMMP2KMT2ALMNAKCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | ALDH1A1 1289/4885TSHR 4275/4885MMP2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.